NBIX News and Press, Neurocrine Biosciences Inc. From 05/26/21

Neurocrine once again posted disappointing Ingrezza sales, and while the post-pandemic reopening should help, it likely won't be an immediate recovery. Management is advancing a broad pipeline of high-risk/high-reward candidates into Phase II studies for a range of movement and psychi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ObsEva  (NASDAQ: OBSV ) stock is on the move this morning after the Swiss biopharma reported positive results from trials of its Yselty treatment for uterine fibroids. OBSV stock was up 5.65% in pre-market trading...

Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference PR Newswire SAN DIEGO , May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m....

Barclays has upgraded shares of Neurocrine Biosciences (NBIX) from equal weight to overweight while maintaining a price target of $110.Given yesterday's closing price, that assumes upside of ~20%.Yesterday, Neurocrine's Q1 earnings missed on both revenue and EPS.Analyst Carter Gould writ...

Image source: The Motley Fool. Neurocrine Biosciences Inc (NASDAQ: NBIX) Q1 2021 Earnings Call May 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Neurocrine Biosciences Inc (NBIX) Q1 2021 Earnings Call Transcrip...

The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Neurocrine Biosciences, Inc. 2021 Q1 - Results - Earnings Call Presentation

Neurocrine Biosciences (NBIX): Q1 Non-GAAP EPS of $0.49 misses by $0.24; GAAP EPS of $0.33 misses by $0.17.Revenue of $236.6M (-0.2% Y/Y) misses by $15.21M.Press Release For further details see: Neurocrine Biosciences EPS misses by $0.24, misses on revenue

Neurocrine Biosciences Reports First Quarter 2021 Financial Results INGREZZA® (valbenazine) First Quarter 2021 Net Product Sales of $230 Million with Approximately 43,300 TRx Initiated Pediatric Phase III Registrational Program of Crinecerfont for the Treatment of Class...

Palm Beach, FL – May 5, 2021 – Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.  Symptoms generally develop sl...

Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference PR Newswire SAN DIEGO , May 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m....